Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- New GSK Japan President to Take Office on Feb. 1
January 30, 2018
- Sanofi to Launch Antibody Drug Dupilumab for Atopic Dermatitis this Spring, Sets Up Special Marketing Force for Potential Blockbuster
January 30, 2018
- New PMP Scheme Will Cause “Pause” before PIII Go/No-Go Decision: Pfizer Japan Head
January 29, 2018
- Takeda Fails in Key Actos Trial for Alzheimer’s
January 26, 2018
- Contract Sales Reps in Japan Log Largest Dip in 2017: Industry Group
January 25, 2018
- Takeda Ramps Up Inisync Pitch in November: Anterio Ranking
January 25, 2018
- Mitobridge Acquisition Completed: Astellas
January 25, 2018
- Swiss Regulator Accepts Edaravone for ALS: Mitsubishi Tanabe
January 24, 2018
- Miraca Inks Exclusive Service Accord with Myriad for Lynparza CDx
January 24, 2018
- Opdivo Earns Gastric Cancer Nod in Taiwan
January 24, 2018
- Adcetris Adds CTCL Indication in Europe
January 24, 2018
- Gilteritinib Grabs EU Orphan Status for AML: Astellas
January 24, 2018
- Biogen Japan to Kick Off PIII Study for Stroke Drug by Year-End
January 24, 2018
- Mitsubishi Tanabe Withdraws Patent Infringement Lawsuit over Radicut Bag against Nissin Pharmaceutical
January 24, 2018
- AnGes’ Gene Therapy Re-Submitted for CLI, This Time for Conditional Approval
January 23, 2018
- Astellas/Vical’s CMV Vaccine Flops in Global PIII
January 23, 2018
- MSD Files for Once-Daily Isentress in Japan
January 23, 2018
- Huahai’s Japan Arm to Focus on Sales of API, Contract Manufacturing; Planning Sales of In-House Products in 10 Years
January 23, 2018
- Eisai Grants Rights for Cancer Agent E7046 to Chinese Immunotherapy Firm
January 22, 2018
- Mochida’s Enbrel Biosimilar Approved, with Ayumi as Distributor
January 22, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…